Clostridium Difficile Infections
9
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
33%
3 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Clostridioides Difficile Infection: Analyzing CLInic Evolution and Bacterial Clearance
Safety Registry of a Fecal Microbiota Transplant Cohort
Virus as Treatment of C. Difficile Infection (VISION)
Treatment of CDI and Recurrence With Fecal Microbiota Transplant Using Promicrobioma
Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients
Faecal Bacteriotherapy for Postantibiotic Diarrhoea in Critically Ill Patients
Prevention of C.Difficile Infections With Oral Vancomycine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Molecular Epidemiology of Clostridium Difficile Infections in Children